Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
AssigneeLaboratoires Serono SA
InventorsGerardo Burton, Carlos P. Lantos, Adriana Silvia Veleiro
Life of this patent
Estimating the term…
Abstract
The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues.
Claims2
A method for reducing thymocyte apoptosis in a human in need thereof, comprising
- administering a composition comprising a compound of formula (IIa) and one or more pharmaceutically acceptable carriers or diluents to the human in need thereof,
- wherein X is S, SO or SO2, in an amount effective for reducing thymocyte apoptosis.
A method for reducing thymocyte apoptosis in a human in need thereof, comprising
- administering a composition comprising a compound of formula (II) and at least one pharmaceutically acceptable carrier or diluent to the human in need thereof,
- wherein X is S, SO, or SO2, and R is H or OH, in an amount sufficient to reduce the apoptosis.
Dependencies are inferred from the claim text.